If you’re a current subscriber, log in below. If you would like to subscribe, please click the subscribe tab above.
Username and Password Help
By MATTHEW PERRONE
AP Health Writer
WASHINGTON (AP) — Drugmaker Merck asked U.S. regulators Monday to author- ize its pill against COVID-19 in what would add an entirely new and easy-to-use weapon to the world’s arsenal against the pandemic.
If cleared by the Food and Drug Administration — a decision that could come in a matter of weeks — it would be the first pill shown to treat COVID-19. All other FDA- backed treatments against the disease require an IV or injec- tion.
An antiviral pill that people could take at home to reduce their symptoms and speed recovery could prove ground- breaking, easing the crushing caseload on U.S. hospitals and helping to curb outbreaks in poorer countries with weak health care systems. It would also bolster the two-pronged approach to the pandemic: treatment, by way of medication, and prevention, primarily through vaccinations.
The FDA will scrutinize com- pany data on the safety and effectiveness of the drug, mol- nupiravir, before rendering a decision.
Merck and its partner Ridgeback Biotherapeutic said they specifically asked the agency to grant emergency use for adults with mild-to-moderate COVID-19 who are at risk for severe disease or hospitalization. That is roughly the way COVID-19 infusion drugs are used.
“The value here is that it’s a pill so you don’t have to deal with the infusion centers and all the factors around that,” said Dr. Nicholas Kartsonis, a senior vice president with Merck’s infectious disease unit. “I think it’s a very power- ful tool to add to the toolbox.”
The company reported earli- er this month that the pill cut hospitalizations and deaths by half among patients with early symptoms of COVID-19. The results were so strong that independent medical experts monitoring the trial recom- mended stopping it early.
Side effects were similar between patients who got the drug and those in a testing group who received a dummy pill. But Merck has not pub- licly detailed the types of prob- lems reported, which will be a key part of the FDA’s review.
Top U.S. health officials continue to push vaccinations as the best way to protect against COVID-19.
“It’s much, much better to prevent yourself from getting infected than to have to treat an infection,” Dr. Anthony Fauci said while discussing Merck’s drug last week.
Still, some 68 million eligible Americans remain unvaccinated, underscoring the need for effective drugs to control future waves of infection.
Since the beginning of the pandemic, health experts have stressed the need for a convenient pill. The goal is for something similar to Tamiflu, the 20-year-old flu medication that shortens the illness by a day or two and blunts the severity of symp- toms like fever, cough and stuffy nose.
Three FDA-authorized antibody drugs have proved highly effective at reducing COVID-19 deaths, but they are expensive, hard to pro- duce and require specialty equipment and health pro- fessionals to deliver.
Assuming FDA authoriza- tion, the U.S. government
has agreed to buy enough of the pills to treat 1.7 million people, at a price of roughly $700 for each course of treatment. That’s less than half the price of the antibody drugs purchased by the U.S. government — over $2,000 per infusion — but still more expensive than many antivi- ral pills for other conditions.
Merck’s Kartsonis said in an interview that the $700 figure does not represent the final price for the medication.
“We set that price before we had any data, so that’s just one contract,” Kartsonis said. “Obviously we’re going to be responsible about this and make this drug as accessible to as many people around the world as we can.”
Kenilworth, New Jersey- based Merck has said it is in purchase talks with govern- ments around the world and will use a sliding price scale based on each country’s economic means. Also, the company has signed licensing deals with several Indian generic drugmakers to produce low-cost versions of the drug for lower-income countries.
Several other companies, including Pfizer and Roche, are studying similar drugs and are expected to report results in the coming weeks and months. AstraZeneca is also seeking FDA authoriza- tion for a long-acting anti- body drug intended to provide months of protection for patients who have immune- system disorders and do not adequately respond to vacci- nation.
Eventually some experts predict various COVID-19 therapies will be prescribed in combination to better pro- tect against the worst effects of the virus.